Oncotarget

Corrections:

Correction: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer

PDF  |  How to cite

Oncotarget. 2025; 16:679-679. https://doi.org/10.18632/oncotarget.28765

Metrics: PDF 25 views  |   ?  

Valentina Belli1, Vincenzo Sforza1, Claudia Cardone1, Erika Martinelli1, Giusi Barra2, Nunzia Matrone1, Stefania Napolitano1, Floriana Morgillo1, Concetta Tuccillo3, Alessandro Federico3, Marcello Dallio3, Carmelina Loguercio3, Antonietta Gerarda Gravina3, Raffaele De Palma2, Fortunato Ciardiello1, Teresa Troiani1

1 Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale “F. Magrassi”, Università degli Studi della Campania “Luigi Vanvitelli”, Napoli, Italy
2 Medicina Interna, Dipartimento di Internistica Clinica e Sperimentale “F. Magrassi”, Università degli Studi della Campania “Luigi Vanvitelli”, Napoli, Italy
3 Gastroenterologia, Dipartimento di Internistica Clinica e Sperimentale “F. Magrassi”, Università degli Studi della Campania “Luigi Vanvitelli”, Napoli, Italy

Published: August 28, 2025

Copyright: © 2025 Belli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 3B, the caspase 3 blot in the SW-48 column is an accidental duplicate of the caspase 3 blot in the HC-15 column. The corrected Figure 3B, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:68305-68316. DOI: https://doi.org/10.18632/oncotarget.20054.

Figure 3: Effects of regorafenib in combination with silybin on induction of apoptosis in SW48, SW48-CR, HCT15 and SW480 colon cancer cells. (A) Apoptosis was evaluated with Annexin-V-FITC staining and 7-Amino-Actinomycin D (7-AAD) detection assays using flow cytometry in SW48, SW48-CR, HCT15 and SW480 cancer cells after 24 hours of incubation with silybin (90 μM) or regorafenib (2 μM) and their combination. Histogram of data expressed as percentage of apoptotic cells.*p < 0.05 compared to single treatment. (B) Colon cancer cells were treated with silybin (90 μM) or regorafenib (2 μM) and their combination for 24 hours. Expression of PARP, caspase 3 and 9 were evaluated by immunoblotting as described in Materials
and Methods. α-Tubulin was used as the loading control.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28765